Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling
- 1 July 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (1) , 305-312
- https://doi.org/10.1182/blood-2006-07-033209
Abstract
Interferon (IFN) signaling induces the expression of interferon-responsive genes and leads to the activation of pathways that are involved in the innate immune response. Ubp43 is an ISG15-specific isopeptidase, the expression of which is activated by IFN. Ubp43 knock-out mice are hypersensitive to IFN-α/β and have enhanced resistance to lethal viral and bacterial infections. Here we show that in addition to protection against foreign pathogens, Ubp43 deficiency increases the resistance to oncogenic transformation by BCR-ABL. BCR-ABL viral transduction/transplantation of wild-type bone marrow cells results in the rapid development of a chronic myeloid leukemia (CML)–like myeloproliferative disease; in contrast, a significantly increased latency of disease development is observed following BCR-ABL viral transduction/transplantation of Ubp43-deficient bone marrow cells. This resistance to leukemic development is dependent on type 1 IFN (IFN-α/β) signaling in Ubp43-deficient cells. Increased levels of type 1 IFN are also detected in the serum of CML mice. These results suggest that inhibition of Ubp43-negative effect on IFN signaling can potentiate the response to increased endogenous IFN levels in innate immune responses against cancer development, indicating that pharmacological inhibition of Ubp43 may be of benefit in cancers and others diseases in which interferon is currently prescribed.Keywords
This publication has 70 references indexed in Scilit:
- Microarray analysis reveals that Type I interferon strongly increases the expression of immune-response related genes in Ubp43 (Usp18) deficient macrophagesBiochemical and Biophysical Research Communications, 2007
- UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activityThe EMBO Journal, 2006
- Discontinuation of imatinib therapy after achieving a molecular responseBlood, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001
- Interferons α and β as Immune Regulators—A New LookPublished by Elsevier ,2001
- Cloning and Characterization of a Novel Human Ubiquitin-Specific Protease, a Homologue of Murine UBP43 (Usp18)Genomics, 2000
- The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivityThe Journal of Experimental Medicine, 1999
- P210 and P190 Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family MembersJournal of Biological Chemistry, 1996
- Functional Role of Type I and Type II Interferons in Antiviral DefenseScience, 1994